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Abstract 
Non-substrate-like inhibitors of glycosyltransferases are sought after as chemical tools 
and potential lead compounds for medicinal chemistry, chemical biology and drug 
discovery. Here, we describe the discovery of a novel small molecular inhibitor 
chemotype for LgtC, a retaining α-1,4-galactosyltransferase involved in bacterial 
lipooligosaccharide biosynthesis. The new inhibitors, which are structurally unrelated to 
both the donor and acceptor of LgtC, have low micromolar inhibitory activity, comparable 
to the best substrate-based inhibitors. We provide experimental evidence that these 
inhibitors react covalently with LgtC. Results from detailed enzymological experiments 
with wild-type and mutant LgtC suggest the non-catalytic active site residue Cys246 as a 
likely target residue for these inhibitors. Analysis of available sequence and structural 
data reveals that non-catalytic cysteines are a common motif in the active site of many 
bacterial glycosyltransferases. Our results can therefore serve as a blueprint for the 
rational design of non-substrate-like, covalent inhibitors against a broad range of other 
bacterial glycosyltransferases. 
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1. Introduction 
Glycosyltransferases (GTs) are key enzymes for the biosynthesis of complex glycans 
and glycoconjugates in all domains of life [1]. In bacteria, GT activity is required for 
virulence and viability, and individual GTs are emerging as novel targets for anti-
microbial and anti-virulence drug discovery [2,3]. Small molecular inhibitors of GTs are 
therefore sought after as chemical tools for the interrogation, manipulation and 
disruption of cellular glycosylation pathways [4], and as potential lead compounds for 
drug discovery. Most existing GT inhibitors are substrate analogues that are structurally 
derived from the respective GT donor and/or acceptor [5]. Such substrate-based GT 
inhibitors are usually not drug-like and often suffer from modest bioactivity and/or 
intrinsic physicochemical liabilities, such as limited stability and poor cell penetration. 
While some of these drawbacks can be circumnavigated by using metabolic precursors 
[6-8], the identification of alternative, non-substrate-like GT inhibitors remains an 
important goal in medicinal chemistry and chemical biology [9]. Despite recent progress 
[10,11], very few such non-substrate-like GT inhibitors are currently available, in stark 
contrast to other enzyme classes of similar size and biological importance (e.g. kinases, 
proteases). 
Covalent enzyme inhibitors are currently undergoing a renaissance in chemical 
biology [12] and drug discovery [13]. Covalent inhibitors generally display a range of 
attractive features, including high potency, prolonged duration of action, and amenability 
to rational design. A systematic study has recently shown that even reactive 
electrophiles, such as the Michael acceptor acrylamide, do not react indiscriminately 
with any biological nucleophile [14]. This differential reactivity can be harnessed for the 
development of covalent inhibitors, especially those that target non-catalytic residues 
[15]. This approach has been used successfully for inhibitor development against 
several challenging enzyme targets, including drug-resistant kinases [16] and proteases 
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[17]. The covalent targeting of non-catalytic residues, in particular cysteines, therefore 
represents a promising strategy for inhibitor development against intractable targets 
such as GTs. To date, no inhibitors with this mode of action have been reported for any 
bacterial GT. This is particularly striking, as non-catalytic cysteines are a common motif 
in the active site of bacterial GTs. Even beyond bacterial enzymes, there is only a single 
mechanistically related example in the entire GT family [11]. Inhibitors of the mammalian 
O-linked N-acetylglucosamine transferase (OGT) act via an unusual double-
displacement mechanism, which draws on the unique architecture of this enzyme – not 
found in other GTs – and requires a very specific arrangement of two separate target 
residues [11]. 
Herein, we describe a new class of non-substrate-like, covalent inhibitors of the 
retaining -1,4-galactosyltransferase LgtC from Neisseria meningitidis. LgtC catalyzes 
the transfer of D-galactose (D-Gal) from a UDP-Gal donor to a lactose acceptor (Fig. 1A) 
[18]. In pathogenic Gram-negative bacteria such as Neisseria and Haemophilus, LgtC is 
required for the biosynthesis of the terminal digalactoside epitope -D-Galp-(1,4)--D-
Galp in the lipooligosaccharide (LOS) structures of the outer core of the cell envelope 
[19]. LgtC expression has been associated with high-level serum resistance in non-
typeable Haemophilus influenzae (NTHi) [19], and inhibition of LgtC and related GTs 
that are involved in LOS biosynthesis has been suggested as a strategy for anti-
microbial drug discovery [18]. LgtC is an excellent starting point for such an approach 
not only because of its role in bacterial virulence, but also because of its structural and 
mechanistic communalities with other bacterial GTs [18], which have made it a widely 
used model system for mechanistic and structural studies in this enzyme family. 
We have identified small molecular inhibitors of LgtC that are structurally 
unrelated to both the LgtC donor and acceptor (Fig. 1B). We demonstrate that these 
inhibitors act via a covalent mechanism of inhibition, targeting a non-catalytic cysteine 
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residue in the LgtC active site. Analysis of sequence and structural data shows that 
active-site cysteines are a common feature in bacterial GTs. Our results may therefore 
serve as a blueprint for the rational development of non-substrate-like, covalent 
inhibitors of other bacterial enzymes in this family. 
 
Figure 1 (A) The LgtC reaction, and its inhibition by pyrazol-3-one 1.a (B) Chemical 
structures of pyrazol-3-ones 1-3. 
 
 
 
 
 
aAssay conditions: LgtC (activated with 5 mM DTT), lactose (2 mM), UDP-Gal (28 µM), 
MnCl2 (5 mM), CIP (10 U/ml), CEL (1 mg/ml), Triton (0.01%) and inhibitor (0.1-100 µM) 
were incubated in HEPES buffer (pH 7.0) for 20 min at 30 °C. The progress of the 
reaction was determined with malachite green as previously described [20]. 
 
 
2. Results and discussion 
2.1 Rationale and chemical synthesis of inhibitors. We have recently adapted a 
biochemical GT assay for inhibitor studies with non-substrate-like chemotypes [20]. We 
have subsequently used this assay to evaluate a collection of 130 small molecules as 
potential non-substrate-like inhibitors of LgtC. The collection was designed around 
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structural scaffolds that are known from other GT inhibitors, including nucleosides, 
steroids, and pyrazol-3-ones (Fig. 1B). Pyrazol-3-ones have previously been reported as 
screening hits against other GTs [21,22], but their molecular mode of action has not 
been investigated. From our own screen against LgtC, pyrazol-3-one 1 emerged as the 
most promising hit from this series and is the primary target molecule of the present 
study. 1 was synthesized in two steps from phenylhydrazine via a ring-closing 
condensation with ethyl acetoacetate, followed by a Knoevenagel condensation with 2-
trifluoromethyl benzaldehyde (Scheme 1). This synthesis was readily adapted to also 
provide access to the congeners 2 and 3 (Scheme 1). 
 
Scheme 1 Synthesis of target molecules 1-3.a 
 
 
aReagents & conditions: (i) ethyl 3-oxobutanoate, acetic acid, 110 ºC, 97% (6) or ethyl 
4,4,4-trifluoroacetoacetate, acetic acid, 110 ºC, 72% (7); (ii) 2-(trifluoromethyl) 
benzaldehyde, acetic acid, reflux, 48% (for 1); (iii) 3-(benzyloxy)benzaldehyde (for 2) or 
3-bromo-4-methoxybenzaldehyde (for 3), 160 oC/microwave, 15 min, 53% (2) or 75% (3) 
 
2.2 Biochemical evaluation of inhibitors. In initial experiments, pyrazol-3-one 1 inhibited 
LgtC with an IC50 value of 27 μM (Fig. 1A). All inhibition assays were carried out in the 
presence of surfactant to suppress non-specific aggregation and avoid assay artefacts 
[23]. This assay protocol provided confidence that the inhibitory activity of 1 was 
genuine. Equally importantly, 1 showed no inhibitory activity in control experiments 
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against the calf intestinal phosphatase (CIP) used as a secondary enzyme in the 
biochemical assay (SI). 
We hypothesised that 1 may act as a covalent inhibitor towards LgtC, due to the 
presence of the Michael acceptor system, which is a known cysteine-reactive 
electrophile in covalent inhibitors and probes [24]. As no reports on pyrazol-3-ones as 
covalent enzyme inhibitors have previously been published, we set out to experimentally 
test this hypothesis. First, we compared enzyme activity in the assay mixture of LgtC 
and 1 before and after diafiltration. The inhibitory activity of 1 was preserved after 
diafiltration, which strongly suggested a covalent mode of inhibition (Fig. 2). 
 
Figure 2 LgtC activity in the presence of inhibitor 1, before and after diafiltration.a 
 
 
 
aConditions: LgtC (activated with 5 mM DTT) was pre-incubated with inhibitor (100 M) 
or DMSO, in the presence of UDP-Gal (28 µM), for 10 min at 30 °C. Lactose (2 mM) was 
added, and the reactions were incubated for 20 min at 30 °C. Samples were drawn, and 
enzyme activity before diafiltration was determined under standard assay conditions. 
Enzyme reactions (3 mL) were subjected to diafiltration in Vivaspin concentrator tubes 
(centrifugation at 4 °C, 4000 rpm). The initial residual volume (300 µL) was washed once 
with HEPES buffer (pH 7.0, total volume 3 mL). The residual volume (300 µL) from the 
wash step was diluted to 450 µL with HEPES buffer (pH 7.0), and enzyme activity after 
diafiltration was determined under standard assay conditions (2 mM lactose, 28 µM 
UDP-Gal, 20 min incubation at 30 °C). Each experiment was carried out in triplicate 
(100% activity = complete conversion of UDP-Gal). Error bars represent standard 
deviation. 
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Next, we directly analysed the reaction of LgtC with 1 by mass spectrometry. 
These experiments showed the formation of a covalent adduct, providing direct evidence 
for the covalent reaction of 1 and LgtC (Fig. 3A). Importantly, only a single adduct was 
observed in these experiments, at a 1:1 ratio of inhibitor and enzyme. This suggests that 
1 reacts only with a single residue in LgtC. 
 
Figure 3 Mass spectrometry reveals the formation of covalent adducts of LgtC with 
pyrazol-3-ones 1 (panel A), 2 (panel B) and 3 (panel C).a 
 
A 
 
B 
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C 
 
 
aConditions: LgtC in HEPES buffer (pH 7.0) was incubated with inhibitor (1 and 2: 100 
µM in DMSO; 3: 50 µM in DMSO) for 20 min at 30 °C (10% final DMSO concentration). 
Samples were directly analysed by electrospray mass spectrometry. 
 
Figure 4 1H-NMR spectra of the time-dependent, covalent reaction of 1 with 
cysteine.a 
 
 
 
aConditions: Solutions of 1 (19.8 mg, 0.06 mmol, in d6-DMSO) and L-cysteine (7.26 mg, 
0.06 mmol, in d6-DMSO) were mixed in a glass NMR tube. 1H-NMR spectra were 
recorded at various time points from 0 min to 190 min ( 3.3 ppm: H2O). 
CH3 (E-/Z-isomers) 
CH 
 
 
CH 
 
 
CH3 (diastereomers) 
N
N
O
CH3
CF3
H
N
N
OH
CH3
CF3
S
CO2
H3N
H
cysteine 
 
 
  
 - 10 - 
In order to identify potential target residues for the covalent reaction, we 
incubated 1 separately with three amino acids containing different side chain 
nucleophiles (L-cysteine, L-serine and L-lysine), and followed the individual reactions by 
1H-NMR. The time-dependent formation of a covalent adduct at the exocyclic double 
bond was observed upon incubation of 1 with L-cysteine (Fig. 4), but not with L-serine or 
L-lysine (SI). These results show that under otherwise identical conditions, the Michael 
acceptor system in 1 reacts preferentially with a sulfur nucleophile. 
This preference suggested that the target residue in LgtC may be a cysteine, 
although the reactivity of a specific residue in the environment of the protein will 
necessarily depend on neighboring groups. LgtC contains five cysteines, of which three 
are solvent-accessible [18]. One of these is Cys246, which sits at the interface of the 
LgtC acceptor and donor binding sites, in close proximity to the lactose acceptor (SI, Fig. 
S1). Molecular simulations using a covalent docking protocol [25] suggested that 1 is 
binding at the substrate binding site of LgtC in an ideal orientation for the covalent 
reaction of the Michael acceptor system with Cys246 (SI, Fig. S1). In order to 
experimentally test the hypothesis that 1 may indeed bind at the substrate binding site, 
we investigated the effect the concentration of the LgtC acceptor, lactose, may have on 
inhibition. Under standard assay conditions (no pre-incubation, turnover 20-50%), 
inhibitory activity decreased markedly at higher acceptor concentrations (Fig. 5A). 
Qualitatively, this is consistent with an acceptor-competitive binding mode for 1. In order 
to obtain quantitative data and enable detailed enzyme kinetics analysis, we repeated 
this experiment at turnover rates of <10%, at a fixed concentration of UDP-Gal donor 
(100 M), and variable concentrations of lactose acceptor (5-25 mM) and inhibitor (1-5 
M). Dixon and Cornish-Bowden analyses of the resulting data show that under these 
conditions, 1 acts as a competitive inhibitor of LgtC relative to the lactose acceptor (Fig. 
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5B). These results show that 1 does indeed bind at the substrate binding site, as 
required for a potential covalent reaction with Cys246. 
 
Figure 5 Effect of different acceptor concentrations on the inhibitory activity of 
pyrazol-3-one 1 towards LgtC under standard assay conditions (A) and enzyme kinetics 
conditions (B). 
 
A Standard assay conditions (donor turnover 20-50%)a 
 
 
aConditions: LgtC was incubated with 1 (0.1-100 µM), UDP-Gal (28 µM), MnCl2 (5 mM), 
CIP (10 U/ml), CEL (1 mg/ml), Triton (0.01%) and lactose acceptor (2-50 mM) for 20 min 
at 30 °C in 13 mM HEPES buffer (pH 7.0). Each experiment was carried out in triplicate. 
 
 
B Enzyme kinetics conditions (donor turnover <10%)a 
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aConditions: LgtC was incubated with 1 (1-5 µM), UDP-Gal (100 µM), MnCl2 (5 mM), CIP 
(10 U/ml), CEL (1 mg/ml), Triton (0.01%) and lactose acceptor (5-25 mM) for 20 min at 
30 °C in 13 mM HEPES buffer (pH 7.0). Data points were fitted to a Dixon or Cornish-
Bowden plot with GraFit 7. 
 
In order to investigate the role of Cys246 for the inhibitory activity of 1, we created 
two LgtC mutants, in which Cys246 is replaced with a non-nucleophilic (C246A) or only 
weakly nucleophilic (C246S) residue. Both mutants were catalytically active under our 
standard conditions, albeit less so than wild-type LgtC. At the highest enzyme 
concentration tested, the observed turnover of donor was approximately 36% (C246A) 
or 22% (C246S) of that of the wild-type enzyme (SI). This level of enzymatic activity was 
sufficient for inhibition experiments. Under the standard assay conditions, pyrazol-3-one 
1 at the highest concentration (100 μM) showed only weak inhibition against C246S 
LgtC, and almost none against C246A LgtC (Fig. 6). These results provide direct 
evidence that Cys246 is a critical residue for the inhibition of LgtC by pyrazol-3-one 1, 
possibly as the target for a covalent interaction with the inhibitor. They also suggest that 
1 is only weakly effective as a non-covalent inhibitor of LgtC, at least at the 
concentrations tested. 
 
Figure 6 Compound 1 shows only weak inhibition of the LgtC mutants C246A and 
C246S.a 
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aConditions: LgtC was incubated with 1 (0.1-100 µM), UDP-Gal (28 µM), MnCl2 (5 mM), 
CIP (10 U/ml), CEL (1 mg/ml), Triton (0.01%) and lactose acceptor (2 mM) for 20 min at 
30 °C in 13 mM HEPES buffer (pH 7.0). Control experiments without inhibitor were 
carried out in parallel, showing a donor turnover of, respectively, 23% (wild-type), 21% 
or 39% (C246A), and 26% (C246S). Each experiment was carried out in triplicate. 
 
To further dissect the structural requirements for the interaction between 1 and 
LgtC, we next carried out inhibition experiments with structural analogues of 1 (SI). As 
expected, compound 4, a hydrogenated variant of 1 lacking the exocyclic double bond 
and hence the capacity for covalent interaction, showed no inhibitory activity against 
LgtC (SI, Table S1). Compound 5, which contains a different heterocyclic scaffold, but 
the same Michael acceptor system as pyrazol-3-one 1, was also inactive (SI, Table S1). 
The lack of activity of compounds 4 and 5 shows that the Michael acceptor system in 1 
is necessary, but not sufficient, for the inhibition of LgtC. It suggests that non-covalent 
interactions also contribute to the LgtC inhibitory activity of 1, probably by orienting the 
inhibitor correctly in the substrate binding site prior to a covalent interaction with Cys246. 
The substrate binding sites of GTs with the same donor and/or acceptor are 
highly conserved. We therefore decided to explore the behaviour of 1 against three other 
GTs (Table 1), which use either the same UDP-Gal donor (bovine -1,4-GalT) or the 
same lactose acceptor (Pasteurella multocida α-2,3-SiaT, human FUT-2) as LgtC, but 
lack an active-site cysteine. Pyrazol-3-one 1 was inactive against all three of these GTs 
(Table 1 & SI). These results demonstrate that 1 does not act simply as a non-covalent 
GT substrate mimic. Taken together, our results suggest strongly that it is the capacity to 
bind non-covalently at the substrate binding site of LgtC, in combination with a covalent 
interaction, most likely with Cys246, which forms the basis for the inhibitory activity of 1 
towards LgtC. 
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Table 1 Substrate specificities and inhibition of four glycosyltransferases1 
GT Organism 
Donor 
substrate 
Acceptor 
substrate 
Inhibition 
(cmpd 1) 
LgtC Neisseria meningitidis UDP-Gal β-lactose 27 ± 5 μM2 
β-1,4-GalT Bos taurus UDP-Gal GlcNAc no inhibition3 
α-2,3-SiaT Pasteurella multocida CMP-Neu5Ac β-lactose no inhibition4 
FUT-2 H. sapiens GDP-Fuc α-lactose no inhibition4 
1For experimental details of the inhibition experiments see SI; 2IC50; 
3at highest 
concentration of inhibitor (100 μM); 4at highest concentration of inhibitor (150 μM) 
 
Having established that prototype pyrazol-3-one 1 does indeed act via a covalent 
mode of action, we set out to improve the potency of this new LgtC inhibitor class. To 
increase the reactivity of the Michael acceptor system, we replaced the 5-CH3 group in 1 
with a strongly electron-withdrawing 5-CF3 group (Fig. 1B). The exact 5-CF3 congener of 
1, bearing a (2-trifluoromethyl)benzylidene substituent in position 4, was not synthetically 
accessible. We therefore introduced alternative benzylidene substituents in position 4 
(Fig. 1B). While the new inhibitors 2 and 3 showed no, or only modest, activity under our 
standard assay conditions, their inhibitory activity increased markedly upon pre-
incubation of LgtC with inhibitor, prior to starting the enzyme reaction (Fig. 7 & 8). Such 
a time-dependent inhibition is characteristic for a covalent mode of action. Interestingly, 
the pronounced effect of pre-incubation on inhibitory activity was largely independent of 
the presence of donor or acceptor substrate (Fig. 7, methods B-D). 
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Figure 7 Pre-incubation with LgtC significantly increases the inhibitory activity of 2 
and 3, both in the presence and absence of LgtC substrates.a 
 
  
aConditions: Following pre-incubation (Methods A-D, see Table 2), LgtC was incubated 
with inhibitor (0.1-100 µM), UDP-Gal (28 µM), MnCl2 (5 mM), CIP (10 U/ml), CEL (1 
mg/ml), Triton (0.01%) and lactose acceptor (2 mM) for 20 min at 30 °C in 13 mM 
HEPES buffer (pH 7.0). Each experiment was carried out in triplicate. 
 
 
Table 2 Pre-incubation protocols and enzyme turnovers. 
 
 
Pre-incubation protocol 
Turnover (%)1 
 2 3 
Method A No pre-incubation 29 30 
Method B Pre-incubation (10 min) of LgtC, inhibitor and donor, 
prior to addition of acceptor 
29 30 
Method C Pre-incubation (10 min) of LgtC and inhibitor, 
prior to addition of donor and acceptor 
25 25 
Method D Pre-incubation (10 min) of LgtC, inhibitor and acceptor, 
prior to addition of donor 
23 23 
1Turnover is defined as the percentage consumption of donor UDP-Gal in the 
biochemical assay, relative to the total amount of UDP-Gal used. 
 
For the two inhibitors 2 and 3, inhibitory activity increased consistently with 
increasing pre-incubation time, albeit at different rates, before reaching a plateau after 
60 mins (2) and 20 mins (3), respectively (Fig. 8 & Table 3). The covalent mode of action 
for 2 and 3 was further confirmed with several key experiments, as for the parent 
compound 1. Thus, for both 2 and 3, covalent adducts with LgtC were detected by mass 
spectrometry (Fig. 3B & C), and the time-dependent formation of a covalent adduct with 
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cysteine was observed by 1H NMR (SI). In control experiments, neither 2 nor 3 showed 
activity against CIP or -1,4-GalT (SI). 
 
Figure 8 LgtC inhibition by pyrazolones 2 and 3 at different pre-incubation times. 
For conditions and IC50 values see Table 3. 
 
            
 
 
Table 3 LgtC inhibition by pyrazolones 2 and 3 at different pre-incubation times. 
IC50 values extracted from inhibition curves in Figure 8.
a 
 
 Pre-incubation time (min) 
 0 5 10 20 30 60 180 
2 
IC50 (µM) ± SD 
>100 >50 >50 38 ± 13.0 17.6 ± 1.1 9.0 ± 0.2 6.0 ± 0.2 
LgtC 
turnover (%) 
29 30 41 27 24 29 19 
3 
IC50 (µM) ± SD 
>50 24 ± 7.1 15.8 ± 0.8 6.5 ± 1.6 3.1 ± 0.5 3.1 ± 0.3 5.5 ± 1.2 
LgtC 
turnover (%) 
30 32 46 32 32 39 26 
 
aConditions: LgtC was pre-incubated with inhibitor (2: 0.1-100 µM; 3: 0.1-50 µM) or 
DMSO for the given time (0-180 min) at 30 °C. Lactose (2 mM) and UDP-Gal (28 µM) 
were added, and the reactions were incubated for 20 min at 30 °C. Enzyme activity was 
determined under standard assay conditions. Each experiment was carried out in 
triplicate. 
 
The activity of a covalent inhibitor is governed by two parameters: the strength of 
the initial, non-covalent binding interaction with the target enzyme, and the reactivity of 
the electrophilic warhead (Fig. 9). In order to dissect the contribution of these two steps 
towards the overall activity of 2 and 3, we determined kobs at different inhibitor 
concentrations. By plotting kobs over inhibitor concentration, the kinetic parameters for 
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the first (Ki) and second (kinact) interaction step can be extracted [13]. This analysis 
shows that kinact for both 2 and 3 is of a similar order of magnitude, whereas Ki is about 
10-times greater for compound 2 than for 3. These results suggest that due to the 
different substitution pattern of the 4-substituent, 2 and 3 differ significantly in their non-
covalent binding affinity for LgtC, but not so much in the reactivity of the Michael 
acceptor system. This profile corresponds to the results from experiments with different 
pre-incubation times, which show that 2 requires a longer pre-incubation period for 
maximal activity than 3 (Table 3). The different non-covalent affinities of 2 and 3 are also 
consistent with the slightly different binding modes that were obtained for both inhibitors 
from covalent docking simulations. These docking results suggest that both 2 and 3 can 
bind at the substrate binding site of LgtC in an orientation that allows a covalent reaction 
with residue Cys246, but that the smaller 3-bromo-4-methoxyphenyl substituent in 3 can 
be more readily accommodated than the bulky 3-benzyloxyphenyl substituent in 2 (SI, 
Fig. S1). 
 
Figure 9 Covalent inhibition kinetics for 2 and 3. 
(a) Two-step model of covalent inhibition. 
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(b) Determination of kinetic parameters kobs, Ki and kinact.
a
 
A Semi-logarithmic plots for the time-dependent inactivation of LgtC at different inhibitor concentrations 
  
B Observed rate constants kobs at different inhibitor concentrations, extracted from the plots in A 
  
 
aConditions:  A LgtC activity was determined at various concentrations of 2 (0.5-200 µM) 
or 3 (0.5-50 µM) and in function of different pre-incubation times (0, 5, 10, 20 and 30 
min). Enzyme activity is expressed as percentage of control (DMSO only) and plotted on 
a semi-logarithmic scale over pre-incubation time. Values for kobs were extracted from 
exponential regression using the equation enzyme activity [%] = Ae-kobs x t. B Observed 
rate constants kobs were extracted from the plots in A, re-plotted over inhibitor 
concentrations, and fitted to the hyperbolic equation kobs = kinact × [I]/(Ki+[I]). From these 
plots, Ki and kinact were obtained as previously described [13]. All experiments were 
performed in triplicate. 
 
3. Conclusions 
Existing inhibitors of the bacterial α-1,4-galactosyltransferase LgtC are substrate 
analogues based on a sugar-nucleotide scaffold [18,26]. Our results establish suitably 
substituted pyrazol-3-ones as the first non-substrate-like, covalent inhibitor chemotype 
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for this enzyme. The activity of inhibitors 2 and 3 upon preincubation is comparable to 
the most potent substrate-based LgtC inhibitors reported to date [26]. Our data suggest 
that pyrazol-3-ones 1-3 bind at the substrate binding site of LgtC prior to the covalent 
reaction, which most likely occurs at the non-catalytic residue Cys246 in the enzyme 
active site. Importantly, the new inhibitors are inactive against three related GTs that use 
either the same donor or acceptor substrate as LgtC, but lack a non-catalytic cysteine in 
the active site. This behaviour is notable, as other pyrazol-3-ones have previously been 
classified as non-selective, pan-assay interfering compounds (PAINS) [27]. It suggests 
that, while it is likely that the unoptimised inhibitors 1-3 may also react with other 
proteins that contain a carbohydrate- or nucleotide-binding site with a non-catalytic 
cysteine, target selectivity could be engineered into these inhibitors through further 
structural modification. 
Non-catalytic cysteine residues are a common feature of bacterial GTs. In 
principle, the direct targeting of non-catalytic cysteines can therefore serve as a general 
inhibitor discovery strategy against many other bacterial GTs. In the sequence-based 
CAZy database of carbohydrate-active enzymes [28], LgtC is a member of family GT-8. 
Neisseria meningitidis LgtC is the only bacterial member of this CAZy family for which 
structural information is currently available. Sequence alignment with other members of 
CAZy family GT-8 shows that Cys246 in LgtC is part of a highly conserved 6-aa motif, 
which is present in several other GTs from different bacteria (SI, Fig. S2). Interestingly, 
these enzymes are not limited to galactosyltransferases, but also include GTs with other 
substrate specificities as well as GTs with unknown function. 
Beyond family GT-8, structural information is currently available for a total of 48 
GTs from bacterial organisms that have a human host. 23 of these structures, including 
Neisseria meningitidis LgtC, have been solved at a resolution of <3Å and contain a 
ligand in the active site (SI, Table S3). Analysis of these 23 structures reveals that all but 
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three, across 14 different CAZy families, have a non-catalytic cysteine at or near the 
active site. In 11 of these structures, this cysteine is within 8Å of the active site ligand 
(see Fig. 10 for selected examples, and SI, Table S3). This analysis demonstrates that 
the presence of non-catalytic, active site cysteines is widespread in bacterial GTs from 
both Gram-negative and Gram-positive organisms, independent of enzyme substrate 
specificity, CAZy family, overall fold type and biological function (Fig. 10).  
 
Figure 10 Examples for bacterial GTs with non-catalytic active-site cysteines.a 
  
  
  
aProteins are shown in cartoon representation (wheat), active site residues are shown as 
lines (wheat), and the active-site cysteine as sticks (yellow). Substrates or substrate 
analogues are shown as sticks (green). Broken red lines indicate the distance from the 
α-carbon of the non-catalytic cysteine to the nearest atom of the respective ligand. (A) E. 
coli chondroitin polymerase (PDB 2Z87), donor: UDP-GalNAc, CAZy family: GT-2, 
general fold type: A; (B) E. coli glycogen synthase (PDB 2QZS) [40], donor: ADP-Glc, 
CAZy family: GT-5, general fold type: B; (C) Bacteroides ovatus BoGT6a (PDB 4CJC) 
[41], donor: UDP-GalNAc, CAZy family: GT-6, general fold type: A; (D) Bradyrhizobium 
sp. WM9 fucosyltransferase NodZ (PDB 3SIX) [42], donor: GDP-Fuc, CAZy family: GT-
23, general fold type: B; (E) Campylobacter jejuni sialyltransferase-II (PDB 2X61) [29], 
donor: CMP-Neu5Ac, CAZy family: GT-42, general fold type: A variant; (F) Rhodobacter 
sphaeroides cellulose synthase (PDB 4HG6) [43], donor: UDP-Glc, CAZy family: GT-2, 
general fold type: A. 
D C 
F E 
B A 
  
 - 21 - 
 
A representative example is the bifunctional CMP-Neu5Ac:α-2,3/-2,8-
sialyltransferase Cst-II from Campylobacter jejuni [29]. In Cst-II, the non-catalytic 
cysteine residue Cys30 is located to the rear of active site, at a distance of 6.0Å from the 
CMP ligand (SI, Fig. S3). Cst-II is a member of CAZy family GT-42. Sequence 
alignments within this family suggest that Cys30 in Cst-II is part of a conserved 10-aa 
sequence, which is also present in several other bacterial sialyltransferases in this family 
(SI, Fig. S4). 
This analysis, in conjunction with our experimental results, suggests that the 
presence of non-catalytic active site cysteines can be systematically exploited for the 
discovery of new inhibitor classes against a broad range of bacterial GTs, including 
enzymes with very different, or indeed unknown, substrate specificities. In the latter 
case, such inhibitors would be of considerable use to annotate the biochemical and 
biological function of these GTs. Our results provide a blueprint for such an inhibitor 
discovery strategy. Such a strategy will be facilitated further by the recent publication of 
freely available, web-based protocols for covalent docking [25] and virtual screening 
[30]. 
Many of the bacterial GTs that are amenable to this general inhibitor discovery 
strategy are involved in bacterial virulence processes and complex pathogen/host 
interactions [31]. Covalent inhibitors would therefore be eminently useful as tool 
compounds for anti-virulence drug discovery [32], not only for inhibition studies, but also 
as affinity probes for the labelling and imaging of bacterial GTs in vivo. In preliminary 
experiments, we have already successfully used a fluorescent derivative of 1 for the 
labelling of LgtC (unpublished results). Results from this ongoing work will be reported in 
due course. 
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4. Experimental section 
4.1 Chemistry 
All chemical reagents were obtained commercially and used as received. Target 
compounds and synthetic intermediates were purified by flash chromatography column 
and characterized by TLC, 1H-NMR, 13C-NMR, and ESI-MS. Flash chromatography 
columns were packed wet. Thin layer chromatography (TLC) was performed on 
precoated aluminium plates (Silica Gel 60 F254, Merck). Compounds were visualized by 
exposure to UV light (254/365 nm). NMR spectra were recorded on a Bruker BioSpin at 
400 MHz (1H) or 100 MHz (13C). Mass spectra were recorded at the EPSRC National 
Mass Spectrometry Service Centre, Swansea. Analytical HPLC was carried out on 
Agilent 1260 Infinity machine equipped with an Agilent Poroshell 120 EC-C18 column 
(2.7 µm, 4.6 x 50 mm) under the following conditions: 0.1% formic acid in 
water/methanol, flow rate: 0.5 mL/min, detection wavelength: 254 nm. The purity of all 
target compounds was >95%. 
 
4.1.1 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (6). Phenylhydrazine (219 mg, 
2.03 mmol) and ethyl 3-oxobutanoate (264 mg, 2.03 mmol) were dissolved in glacial 
acetic acid. The reaction mixture was stirred at 110 ºC until TLC (hexane/EtOAc 1:1) 
showed complete consumption of the starting material. Upon cooling a white solid 
precipitated from the solution and was filtered and washed with ice-cold ethanol. 
Purification by flash column chromatography afforded the title compound [33] as a light 
yellow solid (343 mg, 1.97 mmol, 97 %). 1H-NMR (400 MHz, CDCl3) δ = 2.26 (s, 3H), 
3.49 (s, 2H), 7.27-7.32 (m, 1H), 7.48-7.54 (m, 2H), 7.96-8.01 (m, 2H) ppm; 13C-NMR 
(100 MHz, CDCl3) δ = 16.9, 43.0, 118.8, 125.0, 128.8, 138.0, 156.4, 170.6 ppm. 
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4.1.2 1-Phenyl-3-(trifluoromethyl)-1H-pyrazol-5-ol (7). The title compound [34] was 
obtained as a white solid (652 mg, 2.86 mmol, 72 %) from phenylhydrazine (433 mg, 4 
mmol) and ethyl 4,4,4-trifluoroacetoacetate (736 mg, 4 mmol) via the method described 
for 6. 1H-NMR (400 MHz, DMSO-d6) δ = 5.94 (s, 1H), 7.39 (t, 1H, J = 8.0 Hz), 7.52 (t, 
2H, J = 8.0 Hz), 7.71 (d, 2H, J = 8.0 Hz), 12.49 (s, 1H) ppm; 13C-NMR (100 MHz, 
DMSO-d6) δ = 85.6, 121.3 (q, 1JCF = 267 Hz), 122.3, 127.2, 129.1, 137.7, 140.4 (d, 
2JCF 
= 37 Hz), 153.7 ppm. 
 
4.1.3 (Z)-5-Methyl-2-phenyl-4-(2-(trifluoromethyl)benzylidene)-2,4-dihydro-3H-pyrazol-3-
one (1). 6 (220 mg, 2.03 mmol) and 2-(trifluoromethyl)benzaldehyde (706 mg, 4.06 
mmol) were dissolved in glacial acetic acid. The reaction was heated to reflux until TLC 
(hexane/EA 3:1) showed complete consumption of starting material. The reaction 
mixture was cooled and the product was isolated by column chromatography. The title 
compound was obtained as an orange solid (320 mg, 0.97 mmol, 48%). 1H-NMR (400 
MHz, CDCl3) δ = 2.36 (s, 3H), 7.18 (t, 1H, J = 8.0 Hz), 7.39 (t, 2H, J = 8.0 Hz), 7.59 (t, 
1H, J = 8.0 Hz), 7.66 (t, 1H, J = 8.0 Hz), 7.77-7.78 (m, 2H), 7.90 (d, 2H, J = 8.0 Hz), 8.49 
(d, 1H, J = 8.0 Hz) ppm; 13C-NMR (100 MHz, CDCl3) δ = 13.1, 118.9, 123.9 (q, 
1JCF = 
272 Hz), 125.1, 126.1 (q, 3JCF = 6 Hz), 128.8, 129.4 (d, 
2JCF = 30 Hz), 129.7 (d, 
3JCF = 2 
Hz), 129.8, 131.3, 131.5, 132.7, 138.0, 141.3, 150.4, 161.0 ppm. ESI-MS: m/z 331.1 
(100 %) [M+H]+, 348.1 (8 %) [M+NH4]
+; HR-MS: m/z 331.1058 [M+H]+, [C18H14F3N2O]
+ 
calcd for 331.1053. HPLC: 98%. 
 
4.1.4 (Z)-4-(3-(Benzyloxy)benzylidene)-2-phenyl-5-(trifluoromethyl)-2,4-dihydro-3H-
pyrazol-3-one (2). 7 (57 mg, 0.25 mmol) and 3-(benzyloxy)benzaldehyde (64 mg, 0.30 
mmol) were placed in a microwave-proof glass tube and heated for 15 min at 160 oC in a 
commercial microwave apparatus. The reaction was cooled to room temperature. The 
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reaction product was precipitated by addition of ethylacetate and hexane, collected by 
filtration, and recrystallized from hexane and ethylacetate. The title compound was 
obtained as orange solid (56 mg, 0.13 mmol, 53%). 1H-NMR (400 MHz, CDCl3) δ = 5.23 
(s, 2H), 7.27-7.33 (m, 2H), 7.35-7.39 (m, 1H), 7.41-7.45 (m, 2H), 7.47-7.53 (m, 5H), 7.76 
(s, 1H), 7.84 (d, 1H, J = 8.0 Hz), 7.92-7.95 (m, 2H), 8.68 (t, 1H, J = 2.0 Hz) ppm; 13C-
NMR (100 MHz, CDCl3) δ = 70.3, 118.1, 119.8 (q, 
1JCF = 270 Hz), 120.1, 121.6, 122.9, 
126.3, 127.9, 128.2, 128.5, 128.6, 129.0, 129.8, 133.8, 136.4, 137.5, 140.7 (d, 2JCF = 37 
Hz), 150.6, 159.0, 161.1 ppm. ESI-MS: m/z 423.1 (91 %) [M+H]+, 455.2 (100 %) 
[M+MeOH+H]+, 477.1 (65 %) [M+MeOH+Na]+; HR-MS: m/z 423.1314 [M+H]+, 
[C24H18F3N2O2] calcd for 423.1315. HPLC: 97%. 
 
4.1.5 (Z)-4-(3-Bromo-4-methoxybenzylidene)-2-phenyl-5-(trifluoromethyl)-2,4-dihydro-
3H-pyrazol-3-one (3). The title compound was obtained as a white solid (80 mg, 0.19 
mmol, 75%) from 7 (54 mg, 0.25 mmol) and 3-bromo-4-methoxybenzaldehyde (65 mg, 
0.30 mmol) under the conditions described for 2. 1H-NMR (400 MHz, CDCl3) δ = 4.05 (s, 
3H), 7.06 (d, 1H, J = 12.0 Hz), 7.30 (t, 1H, J = 8.0 Hz), 7.48 (t, 2H, J = 8.0 Hz), 7.63 (s, 
1H), 7.93 (d, 2H, J = 8.0 Hz), 8.71-8.74 (m, 1H), 8.88 (d, 1H, J = 4.0 Hz); 13C-NMR (100 
MHz, CDCl3) δ = 57.8, 111.6, 112.3, 119.8, 119.9 (q, 
1JCF = 270 Hz), 120.1, 126.3, 
127.0, 129.0, 136.7, 137.6, 140.0, 140.6 (d, 2JCF = 37 Hz), 148.2, 160.9, 161.4 ppm. 
ESI-MS: m/z 425.0 (100 %) [M+H]+, 479.0 (60 %) [M+MeOH+Na]+; HR-MS: m/z 
425.0107 [M+H]+, [C18H13BrF3N2O2]
+ calcd for 425.0107. HPLC: 98%. 
 
4.2 Biochemistry. LgtC was expressed and purified as previously described [26]. 
Recombinant LgtC was activated with DTT (10 mM, in HEPES buffer) in a 1:1 ratio for 
30 min at 30 °C prior to each experiment, unless otherwise stated. For enzyme activity 
and inhibition experiments, we used a recently reported modification [20] of a 
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colorimetric glycosyltransferase assay originally developed by Wu and co-workers [35]. 
All assays were carried out in Nunc clear, flat-bottom 96-well microplates, unless 
otherwise stated. 
 
4.3 Inhibition assays. For IC50 experiments, LgtC activity was adjusted to 20-50% 
turnover of UDP-Gal donor. We have previously shown that within this turnover range 
IC50 values are obtained reproducibly [20]. Assay components were added in the order 
required for the respective experiment (Methods A-D). All concentrations for the assay 
components are final concentrations. 
 
4.3.1 Method A (standard assay protocol): no pre-incubation with inhibitor. Aliquots (15 
µL each) of activated LgtC, MnCl2 (5 mM), chicken egg-white lysozyme (CEL, 1 mg/mL), 
calf-intestinal alkaline phosphatase (CIP, 10 U/mL), Triton (0.01%) and HEPES buffer 
(13 mM, pH 7.0) were combined with lactose acceptor (30 µL, 2 mM) or HEPES buffer 
(30 µL, control for non-specific hydrolysis) in the requisite microplate wells. Inhibitor at 
various concentrations in DMSO (15 µL, 10% final DMSO concentration) or DMSO only 
(15 µL, control) was added. Reactions were started by addition of UDP-Gal donor (15 
µL, 28 µM) and incubated for 20 min at 30 °C. Reactions were stopped by addition of 
Malachite Green reagent A (30 µL) [20]. The microplate was shaken carefully, and 
Malachite Green Reagent B (30 µL) [20] was added. The colour was allowed to develop 
over 20 min, and the absorbance in each well was recorded at 620 nm on a Polarstar 
Optima plate reader (BMG Labtech). The absorbance measurements were used to 
calculate enzyme activity. 
 
4.3.2 Method B: pre-incubation of LgtC with inhibitor, in the presence of donor. Aliquots 
(15 µL each) of activated LgtC, MnCl2 (5 mM), CEL (1 mg/mL), CIP (10 U/mL), Triton 
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(0.01%) and HEPES buffer (13 mM, pH 7.0) were combined with inhibitor at various 
concentrations in DMSO (15 µL, 10% final DMSO concentration) or DMSO only (15 µL, 
control) in the requisite microplate wells. UDP-Gal donor (15 µL, 28 µM) was added, and 
the mixtures were pre-incubated for the requisite time at 30 °C. Lactose acceptor (30 µL, 
2 mM) or HEPES buffer (30 µL, control) were added, and the reactions were incubated 
for 20 min at 30 °C. The reactions were stopped and analysed as described. 
 
4.3.3 Method C: pre-incubation of LgtC with inhibitor. Aliquots (15 µL each) of activated 
LgtC, MnCl2 (5 mM), CEL (1 mg/mL), CIP (10 U/mL), Triton (0.01%) and HEPES buffer 
(13 mM, pH 7.0) were combined with inhibitor at various concentrations in DMSO (15 
µL, 10% final DMSO concentration) or DMSO only (15 µL, control) in the requisite 
microplate wells. The mixtures were pre-incubated for the requisite time at 30 °C. UDP-
Gal donor (15 µL, 28 µM) and lactose acceptor (30 µL, 2 mM) or HEPES buffer (30 µL, 
control) were added, and the reactions were incubated for 20 min at 30 °C. The 
reactions were stopped and analysed as described. 
 
4.3.4 Method D: pre-incubation of LgtC with inhibitor, in the presence of acceptor. 
Aliquots (15 µL each) of activated LgtC, MnCl2 (5 mM), CEL (1 mg/mL), CIP (10 U/mL), 
Triton (0.01%) and HEPES buffer (13 mM, pH 7.0) were combined with inhibitor at 
various concentrations in DMSO (15 µL, 10% final DMSO concentration) or DMSO only 
(15 µL, control) in the requisite microplate wells. Lactose acceptor (30 µL, 2 mM) or 
HEPES buffer (30 µL, control) were added, and the mixtures were pre-incubated for the 
requisite time at 30 °C. UDP-Gal donor (15 µL, 28 µM) was added, and the reactions 
were incubated for 20 min at 30 °C. The reactions were stopped and analysed as 
described. 
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4.4. Data analysis. On each microplate, a UDP calibration curve (0-12.5 µM) was 
included. Wells for the calibration curve comprised of all components of the standard 
reaction except for acceptor (replaced with buffer), inhibitor (replaced with DMSO), and 
UDP-Gal (replaced with UDP). For each experiment, absorbance at 620 nm (AU) was 
converted to [UDP] (µM) using linear regression of the respective calibration curve. A 
negative control (0 µM inhibitor) and a blank value (0 µM inhibitor, 0 µM acceptor) were 
included on each plate in triplicate. After linear regression, subtracting the blank from the 
negative control afforded the assay window. The background value for each inhibitor 
concentration (no acceptor, but otherwise identical components) was subtracted from 
each inhibitor concentration data point. Once corrected for the background, the 
absorbance in the presence of each inhibitor concentration was divided by the assay 
window and represented as a percentage. These percentage values were plotted 
against log [inhibitor] and analysed using GraphPad Prism (version 6) to afford relative 
IC50 values, if the data represented a sigmoidal curve. Each experiment was carried out 
at least in triplicate. 
 
4.5. Inhibition kinetics. The kinetic parameters kobs, Ki and kinact for covalent inhibition by 
2 and 3 were determined with the assay protocols described above, following the 
general approach described by Singh and co-workers [13]. LgtC activity was determined 
at various concentrations of 2 (0.5-100 µM) or 3 (0.5-50 µM) and in function of different 
pre-incubation times (0, 5, 10, 20 and 30 min). Enzyme activity was expressed as 
percentage of control (with DMSO) and plotted on a semi-logarithmic scale over pre-
incubation time. From these plots, the observed rate constant kobs at each inhibitor 
concentration was extracted. kobs values were re-plotted over inhibitor concentrations 
and fitted to a hyperbolic equation (kobs = kinact × [I]/(Ki+[I])) with GraphPad Prism (version 
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6) to obtain the values for Ki and kinact as previously described [13]. All experiments were 
performed in triplicate. 
 
4.6. Acceptor kinetics. The inhibition kinetics of 1 relative to acceptor were determined 
with the standard assay protocol (Method A) at a fixed concentration of UDP-Gal (100 
M) and variable concentrations of 1 (1, 2, 3, 4 and 5 M) and lactose acceptor (5, 15 
and 25 mM). LgtC activity was adjusted to <10% turnover of UDP-Gal donor. The type of 
enzyme inhibition was determined graphically by fitting the relevant set of data points to 
Dixon or Cornish-Bowden plots with GraFit 7 software. 
 
4.7. LgtC mutants. C246A and C246S mutants of LgtC were prepared in the pCWori+ 
vector. Primers (Life Technologies) were designed using the Agilent primer design tool 
available online [36], and mutagenesis performed using the Quikchange Lightning II site-
directed mutagenesis kit (Agilent). Mutations were confirmed by sequencing. The mutant 
plasmids were transformed into the BL21 (DE3) strain of E. coli, and incubated in 1 L of 
LB broth supplemented with 100 μg/mL ampicillin. Cells were incubated at 37 °C until 
the optical density at 600 nm reached 0.6, induced with 0.5 mM IPTG, and incubated 
overnight at 20 °C. Cells were harvested, resuspended in 25 mL of buffer A (20 mM Tris-
HCl, 0.5 M NaCl, 20 mM imidazole pH 8.0) supplemented with one tablet of Complete 
EDTA free protease inhibitor cocktail (Roche), and lysed using a sonicator. The sample 
was clarified by centrifugation at 20,000g, and the protein purified using an ÄKTAxpress 
automated purification system. The sample was first purified over a 1 mL HisTrap crude 
FF column (equilibrated with buffer A) and eluted with buffer A supplemented with 250 
mM imidazole. It was then purified over a Superdex 200 16/600 hr column and eluted 
isocratically with 10 mM HEPES pH 7.0, 0.5 M NaCl. Glycerol was added to 20% (v/v) 
and the samples stored at -80 °C until use. The activity of both mutants and inhibition by 
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compound 1 (method A) were determined in our colorimetric glycosyltransferase assay 
[20]. 
 
4.8. Diafiltration. Aliquots (15 µL each) of activated LgtC, MnCl2 (5 mM), CEL (1 mg/mL), 
CIP (10 U/mL), Triton (0.01%), HEPES buffer (13 mM, pH 7.0), and inhibitor in DMSO 
(100 µM) or DMSO only (control) were combined in individual wells of a 96-well 
microplate. UDP-Gal donor (15 µL, 28 µM) was added, and the reactions were 
incubated for 10 min at 30 °C. Lactose acceptor (30 µL, 2 mM) or HEPES buffer (30 µL, 
control for non-specific hydrolysis) was added to each well, and the reactions were 
incubated for another 20 min at 30 °C. Samples for pre-diafiltration activity 
measurements were diluted with HEPES buffer at a ratio of 1:1 and analysed 
colorimetrically as described. Samples for diafiltration were collected in Vivaspin 
concentrators (MW cut-off: 10 kDa, total volume: 2-6 mL) and kept on ice prior to 
centrifugation. Samples (3 mL) were centrifuged at 4 °C (4000 rpm) for 50 min. The 
residual volume (300 µL) was diluted to 3 mL with HEPES buffer (pH 7.0) and 
centrifuged again for 50 min. The residual volume (300 µL) from the wash step was 
diluted to 450 µL with HEPES buffer (pH 7.0) and combined with aliquots (450 µL each) 
of MnCl2 (5 mM), CEL (1 mg/mL), CIP (10 U/mL), Triton (0.01%) and HEPES buffer (13 
mM, pH 7.0). To this master mix (90 µL), lactose acceptor (30 µL, 2 mM) or HEPES 
buffer (30 µL, control for non-specific hydrolysis) were added, followed by DMSO (15 
µL). Reactions were started by addition of UDP-Gal donor (15 µL, 28 µM), incubated for 
20 min at 30 °C, and analysed colorimetrically as described, to determine enzyme 
activity after diafiltration. 
 
4.9. Time-dependent NMR experiments. A solution of the requisite amino acid (0.06 
mmol; cysteine in d6-DMSO, lysine and serine in D2O) was added to a solution of the 
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requisite inhibitor (1 or 2, 0.06 mmol) in d6-DMSO in a glass NMR tube. The solution 
was mixed thoroughly by shaking, and 1H-NMR spectra were recorded at 298 K on a 
Bruker BioSpin machine at 400 MHz at various time points from 0-190 min. 
 
4.10 Mass spectrometry. A LgtC stock solution (no DTT treatment) was diluted with 
HEPES buffer (13 mM, pH 7.0) and incubated with inhibitor (1 and 2: 100 µM in DMSO; 
3: 50 µM in DMSO) for 20 min at 30 °C (10% final DMSO concentration). Samples were 
directly analysed by electrospray mass spectrometry on a Waters LCT Premier machine 
(injection volume: 10 μL; desolvation temperature: 350 °C; source temperature: 120 °C). 
 
4.11 Molecular docking protocol. Starting files for inhibitors 1-3 in .mol2 format were 
prepared in MarvinSketch [37]. Structures were energy minimized in UCSF Chimera 
version 1.8 [38] with the following settings: Steepest Descent Steps: 100, Steepest 
Descent Step size (A): 0.02, Conjugate Gradient Steps: 100, Conjugate Gradient Step 
size (A): 0.02, Update interval: 10, Fixed atoms: none. Covalent docking was carried out 
on the CovalentDock Cloud server [25] with the following settings: receptor PDB file 
1GA8 [18], binding site Cys246, ligand: minimized starting files for inhibitors 1-3. 
Docking results were analysed with MacPyMOL [39]. 
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